

DO YOU HAVE gMG PATIENTS LIKE MADISON?

Learn about her story and the types of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive and may be appropriate for treatment with ULTOMIRIS^{®1}

Image is not of actual patient.

INDICATION

ULTOMIRIS is indicated for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.

SELECT IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTIONS

ULTOMIRIS, a complement inhibitor, increases the risk of serious infections caused by *Neisseria meningitidis* [see *Warnings and Precautions (5.1)*] Life-threatening and fatal meningococcal infections have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early.

- Complete or update vaccination for meningococcal bacteria (for serogroups A, C, W, Y, and B) at least 2 weeks prior to the first dose of ULTOMIRIS, unless the risks of delaying ULTOMIRIS therapy outweigh the risk of developing a serious infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against meningococcal bacteria in patients receiving a complement inhibitor. See *Warnings and Precautions (5.1)* for additional guidance on the management of the risk of serious infections caused by meningococcal bacteria.
- Patients receiving ULTOMIRIS are at increased risk for invasive disease caused by *Neisseria meningitidis*, even if they develop antibodies following vaccination. Monitor patients for early signs and symptoms of serious meningococcal infections and evaluate immediately if infection is suspected.

Because of the risk of serious meningococcal infections, ULTOMIRIS is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called ULTOMIRIS and SOLIRIS REMS [see *Warnings and Precautions (5.2)*].

Please see additional Important Safety Information throughout and accompanying full [Prescribing Information](#) for ULTOMIRIS, including **Boxed WARNING** regarding serious and life-threatening or fatal meningococcal infections.

ULTOMIRIS[®] was proven to deliver improvement in activities of daily living in CHAMPION-MG^{1,2}



CHAMPION-MG was a Phase 3, randomized, double-blind, placebo-controlled trial with an open-label extension (OLE). Patients were randomized to receive either ULTOMIRIS (n=86) or placebo (n=89) for 26 weeks and were subsequently allowed to enter the OLE period for up to 4 years¹⁻³


More than 90% of patients had MGFA class II or III gMG with mild or moderate muscle weakness at baseline.^{1,3,4} Approximately 90% of patients were taking an immunosuppressive therapy (IST) at baseline across both treatment arms.^{1,3,4,a}

- Patients on concomitant ISTs were required to be on stable doses throughout the course of the study, and those medications could be adjusted as necessary during the OLE.³

Among patients in the ULTOMIRIS treatment arm,

Improvements in MG-ADL total scores from baseline were observed within 1 week of treatment and were sustained through Week 26 of treatment.^{1,b}

ULTOMIRIS demonstrated efficacy vs placebo at Week 26 (-3.1 vs -1.4, respectively [P=0.0009])^{1,3}



More than
2x
greater improvement
vs placebo

CHAMPION-MG STUDY LIMITATIONS: Data shown are LS means and 95% confidence intervals (CIs), using a mixed model for repeated measures; 95% CIs were not adjusted for multiplicity.^{1,3}

Time to response was part of the planned efficacy analysis, but the primary endpoint was at Week 26. Therefore, results should be interpreted with caution.

BL, baseline; gMG, generalized myasthenia gravis; LS, least squares; MG-ADL, Myasthenia Gravis Activities of Daily Living; MGFA, Myasthenia Gravis Foundation of America; SD, standard deviation.

^aImmunosuppressive agents include glucocorticoids, azathioprine, cyclophosphamide, cyclosporine, methotrexate, mycophenolate mofetil, or tacrolimus.⁴

^bThe MG-ADL is a categorical scale that assesses the impact on daily function of 8 signs or symptoms that are typically affected in gMG. Each item is assessed on a 4-point scale where a score of 0 represents normal function and a score of 3 represents loss of ability to perform that function. The total score ranges from 0 to 24, with the higher scores indicating more impairment.¹

SELECT IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

- Initiation in patients with unresolved serious *Neisseria meningitidis* infection.

WARNINGS AND PRECAUTIONS Serious Meningococcal Infections

ULTOMIRIS, a complement inhibitor, increases a patient's susceptibility to serious, life-threatening, or fatal infections caused by

Adverse reactions reported in $\geq 5\%$ and at greater frequency than placebo in ULTOMIRIS[®]-treated patients¹

Adverse Reactions	ULTOMIRIS (n=86), n (%)	Placebo (n=89), n (%)
GASTROINTESTINAL DISORDERS		
Diarrhea	13 (15)	11 (12)
Abdominal pain	5 (6)	0
INFECTIONS AND INFESTATIONS		
Upper respiratory tract infection	12 (14)	7 (8)
Urinary tract infection	5 (6)	4 (4)
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS		
Back pain	7 (8)	5 (6)
NERVOUS SYSTEM DISORDERS		
Dizziness	8 (9)	3 (3)

- Serious adverse reactions were reported in 20 (23%) patients with gMG receiving ULTOMIRIS and in 14 (16%) patients receiving placebo¹
- The most frequent serious adverse reactions were infections reported in at least 8 (9%) patients treated with ULTOMIRIS and in 4 (4%) patients treated with placebo¹
- Of these infections, one fatal case of COVID-19 pneumonia was identified in a patient treated with ULTOMIRIS and one case of infection led to discontinuation of ULTOMIRIS¹
- The most frequent adverse reactions occurring in $\geq 10\%$ of patients taking ULTOMIRIS were diarrhea and upper respiratory tract infection¹

gMG, generalized myasthenia gravis.

SELECT IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS (continued)

Serious Meningococcal Infections (continued)

meningococcal bacteria (septicemia and/or meningitis) in any serogroup, including non-groupable strains. Life-threatening and fatal meningococcal infections have occurred in both vaccinated and unvaccinated patients treated with complement inhibitors.

Revaccinate patients in accordance with ACIP recommendations considering the duration of ULTOMIRIS therapy. Note that ACIP recommends an administration schedule in patients receiving complement inhibitors that differs from the administration schedule in the vaccine prescribing information. If urgent ULTOMIRIS therapy is indicated in a patient who is not up to date with meningococcal vaccines according to ACIP recommendations, provide antibacterial drug prophylaxis and administer meningococcal vaccines as soon as possible. Various durations and regimens of antibacterial drug prophylaxis have been considered, but the optimal durations and drug regimens for prophylaxis and their efficacy have not been studied in unvaccinated or vaccinated patients receiving complement inhibitors, including ULTOMIRIS. The benefits and risks of treatment with ULTOMIRIS, as well as those associated with antibacterial drug prophylaxis in unvaccinated or vaccinated patients, must be considered against the known risks for serious infections caused by *Neisseria meningitidis*.

Vaccination does not eliminate the risk of serious meningococcal infections, despite development of antibodies following vaccination.

Closely monitor patients for early signs and symptoms of meningococcal infection and evaluate patients immediately if infection is suspected. Inform patients of these signs and symptoms and instruct patients to seek immediate medical care if they occur. Promptly treat known infections. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early. Consider interruption of ULTOMIRIS in patients who are undergoing treatment for serious meningococcal infection depending on the risks of interrupting treatment in the disease being treated.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information for ULTOMIRIS, including Boxed WARNING regarding serious and life-threatening or fatal meningococcal infections.

Meet Madison, a social worker focused on her career^a



Image is not of actual patient.

Age: 32 years
Duration of disease: 8 months; treatment initiated upon diagnosis
Past hobbies: Bike riding and hiking

^aPatient case is fictitious and is not intended for diagnosis and treatment purposes.

Despite adjusting the dose of her steroid and IST, Madison is still experiencing breakthrough symptoms of intermittent slurring of speech, increased shortness of breath, and lower limb paresis

DISEASE PROFILE

- Rapid progression from oMG to gMG required steroids and ISTs to manage symptoms
- Clinical classification of MGFA class IIIa

CURRENT gMG REGIMEN

- Prednisone 40 mg once daily
 - Initially on low-dose steroids and IST; increased steroids to 80 mg per day, then reduced to 40 mg per day and unable to reduce further
- Azathioprine 150 mg once daily
- Pyridostigmine 60 mg four times daily

FAMILY MEDICAL HISTORY

- Osteoporosis and diabetes mellitus

CURRENT MG-ADL DOMAINS⁵

Intermittent slurring or nasal speech	+1
Normal chewing	+0
Normal swallowing	+0
Shortness of breath with exertion	+1
Extra effort while brushing teeth, but no rest periods needed	+1
Moderate impairment to rise from chair, requiring use of arms	+2
Occasional double vision	+1
No eyelid droop	+0

CURRENT MG-ADL TOTAL SCORE 6

Madison is continuing to experience gMG symptoms as well as weight gain and increased acne. She and her physician are considering adding ULTOMIRIS to her current treatment plan⁶

AR, adverse reaction; IST, immunosuppressive therapy; gMG, generalized myasthenia gravis; MG-ADL, Myasthenia Gravis Activities of Daily Living; MGFA, Myasthenia Gravis Foundation of America; oMG, ocular myasthenia gravis.

Why consider ULTOMIRIS[®] for Madison?



Madison fits the eligibility criteria

For the CHAMPION-MG trial, >90% of patients had MGFA class II or III gMG with mild or moderate muscle weakness at baseline^{3,4}



Madison hopes to see an improvement in her ability to perform activities of daily living

ULTOMIRIS offers adult patients more than 2x greater improvement in MG-ADL total score from baseline at Week 26 vs placebo (-3.1 vs -1.4, respectively [$P=0.0009$])^{1,3,a}



Madison wants to minimize disruptions to her life caused by frequent infusions

ULTOMIRIS may be right for her, as treatment is dosed at predictable 8-week intervals starting 2 weeks after an initial loading dose, and only requires 6 to 7 maintenance infusions per year¹



Madison and her physician are hoping to further decrease her dose of corticosteroids^{6,7}

If you have a patient like Madison who you think could be right for ULTOMIRIS, get them started at gMGStartForm.com.

^aBased on the MG-ADL, a categorical scale that assesses the impact on daily function of 8 signs or symptoms that are typically affected in gMG.¹

AR, adverse reaction; gMG, generalized myasthenia gravis; MG-ADL, Myasthenia Gravis Activities of Daily Living; MGFA, Myasthenia Gravis Foundation of America.

SELECT IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS (continued)

ULTOMIRIS and SOLIRIS REMS

Due to the risk of serious meningococcal infections, ULTOMIRIS is available only through a restricted program called ULTOMIRIS and SOLIRIS REMS.

Prescribers must enroll in the REMS, counsel patients about the risk of serious meningococcal infection, provide patients with the REMS educational materials, assess patient vaccination status for meningococcal vaccines (against serogroups A, C, W, Y, and B) and vaccinate if needed according to current ACIP recommendations two weeks prior to the first dose of ULTOMIRIS. Antibacterial drug prophylaxis must be prescribed if treatment must be started urgently, and the patient is not up to date with both meningococcal vaccines according to current ACIP recommendations at least two weeks prior to the first dose of ULTOMIRIS. Patients must receive counseling about the need to receive meningococcal vaccines and to take antibiotics as directed, signs and symptoms of meningococcal infection, and be instructed to carry the Patient Safety Card at all times during and for 8 months following ULTOMIRIS treatment.

Further information is available at www.UltSolIREMS.com or [1-888-765-4747](tel:1-888-765-4747).

Other Infections

Serious infections with *Neisseria* species (other than *Neisseria meningitidis*), including disseminated gonococcal infections, have been reported.

ULTOMIRIS blocks terminal complement activation; therefore, patients may have increased susceptibility to infections, especially with encapsulated bacteria, such as infections caused by *Neisseria meningitidis* but also *Streptococcus pneumoniae*, *Haemophilus influenzae*, and to a lesser extent, *Neisseria gonorrhoeae*. Patients receiving ULTOMIRIS are at increased risk for infections due to these organisms, even if they develop antibodies following vaccination.

Please see additional Important Safety Information throughout and accompanying full [Prescribing Information for ULTOMIRIS](#), including **Boxed WARNING regarding serious and life-threatening or fatal meningococcal infections.**

SELECT IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS (continued)

Thromboembolic Event Management

The effect of withdrawal of anticoagulant therapy during treatment with ULTOMIRIS has not been established. Treatment should not alter anticoagulant management.

Infusion-Related Reactions

Administration of ULTOMIRIS may result in systemic infusion-related reactions, including anaphylaxis and hypersensitivity reactions. In clinical trials, infusion-related reactions occurred in approximately 1 to 7% of patients, including lower back pain, abdominal pain, muscle spasms, drop or elevation in blood pressure, rigors, limb discomfort, drug hypersensitivity (allergic reaction), and dysgeusia (bad taste). These reactions did not require discontinuation of ULTOMIRIS. If signs of cardiovascular instability or respiratory compromise occur, interrupt ULTOMIRIS and institute appropriate supportive measures.

ADVERSE REACTIONS

Most common adverse reactions in adult patients with gMG (incidence $\geq 10\%$) were diarrhea and upper respiratory tract infection. Serious adverse reactions were reported in 20 (23%) of patients treated with ULTOMIRIS and in 14 (16%) patients receiving placebo. The most frequent serious adverse reactions were infections reported in at least 8 (9%) patients treated with ULTOMIRIS and in 4 (4%) patients treated with placebo. Of these infections, one fatal case of COVID-19 pneumonia was identified in a patient treated with ULTOMIRIS and one case of infection led to discontinuation of ULTOMIRIS.

DRUG INTERACTIONS

Plasma Exchange, Plasmapheresis, and Intravenous Immunoglobulins

Concomitant use of ULTOMIRIS with plasma exchange (PE), plasmapheresis (PP), or intravenous immunoglobulin (IVIg) treatment can reduce serum ravulizumab concentrations and requires a supplemental dose of ULTOMIRIS.

Neonatal Fc Receptor Blockers

Concomitant use of ULTOMIRIS with neonatal Fc receptor (FcRn) blockers (e.g., efgartigimod) may lower systemic exposures and reduce effectiveness of ULTOMIRIS. Closely monitor for reduced effectiveness of ULTOMIRIS.

USE IN SPECIFIC POPULATIONS

Pregnancy Exposure Registry

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ULTOMIRIS during pregnancy. Healthcare providers and patients may call [1-833-793-0563](tel:1-833-793-0563) or go to www.UltomirisPregnancyStudy.com to enroll in or to obtain information about the registry.



Scan QR code or visit the link
(<https://bit.ly/3KEpmzp>)

To report SUSPECTED ADVERSE REACTIONS, contact Alexion Pharmaceuticals, Inc. at **1-844-259-6783** or FDA at **1-800-FDA-1088** or www.fda.gov/medwatch.

Please see accompanying full Prescribing Information for ULTOMIRIS, including Boxed WARNING regarding serious and life-threatening or fatal meningococcal infections.



ULTOMIRIS[®]
(ravulizumab-cwvz)
injection for intravenous use
300 mg/3 mL vial

Image is not of actual patient.

Help your adult patients with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) get started on ULTOMIRIS[®]



Fill out the Patient & Prescriber Start Form

Order the meningococcal vaccination series, provide a prescription for ULTOMIRIS, and enroll your patient in support services, all in one place at gMGStartForm.com.



Talk to your patients about OneSource[™]

OneSource is a comprehensive, complimentary, and personalized patient support program offered by Alexion that provides education, health insurance navigation, community connections, and ongoing support to patients and their caregivers. Your patients can find a local Patient Education Manager in their area by visiting alexiononesource.com/pem-finder.



Enroll in the Risk Evaluation and Mitigation Strategy (REMS) program

Due to the risk of meningococcal infections, ULTOMIRIS is available only through a restricted program under REMS.



Scan to enroll in the REMS Program and see additional requirements. You can also call **1-888-765-4747** for more information.

References: 1. ULTOMIRIS. Prescribing information. Alexion Pharmaceuticals, Inc. 2. Meisel A, et al. *J Neurol*. 2023;270(8):3862-3875. 3. Data on file. Alexion Pharmaceuticals, Inc. 4. Vu T, et al. *NEJM Evid*. 2022;1(5):1-22. 5. Myasthenia.org. MG Activities of Daily Living (MG-ADL). UT Southwestern Medical Center, Dallas, 1997. 6. Johnson S, et al. *Med Sci Monit*. 2021;27:e933296. 7. Sathasivan S. *Nat Clin Pract Neurol*. 2008;4(6):317-327.

ONESOURCE[™]
Personalized Patient Support from Alexion

ALEXION[®]
AstraZeneca Rare Disease

ALEXION, the Alexion logo, ULTOMIRIS, SOLIRIS, and the OneSource logo are registered trademarks and OneSource is a trademark of Alexion Pharmaceuticals, Inc.

© 2024, Alexion Pharmaceuticals, Inc. All rights reserved.
US/ULT-g/0366 V4 10/2024